Skip to main content
Fig. 3 | BMC Medical Ethics

Fig. 3

From: Pharmacy stakeholder reports on ethical and logistical considerations in anti-opioid vaccine development

Fig. 3

Pharmacist-reported (a, b) and student-reported (c, d) familiarity with currently available OUD treatments (a, c) and anti-opioid vaccines (b, d). Pharmacist-reported (e, f) and student-reported (g, h) availability (e, g) and utilization (f, h) of resources for managing OUD. The dotted line indicates the scale midpoint. Data plotted as counts (a–d), percentages (e, g) or mean ± SEM (f, h). Kruskal–Wallis with Dunn’s: **p < 0.01 vs. PDMP; ****p < 0.0001 vs. PDMP; #p < 0.05 vs. dropbox

Back to article page

BMC Medical Ethics

ISSN: 1472-6939

Contact us